血清BNP水平及左房内径对脑梗死合并阵发性房颤的辅助诊断价值
Diagnostic Value of Serum BNP and Left Atrial Diameter in Paroxysmal Atrial Fibrillation with Cerebral Embolism
摘要: 目的:通过比较不同房颤类型引起的心源性脑卒中患者血清脑钠钛(BNP)、D-二聚体、纤维蛋白原、C-反应蛋白(CRP)等指标及超声检测左房前后径大小,评估其在心源性脑梗死患者中合并阵发性房颤诊断中的价值,以指导治疗,预防再栓塞。方法:回顾性收集2017年6月至2020年6月在青岛大学附属医院神经内科接诊合并房颤的急性心源性脑梗死患者185例,其中持续性房颤患者104例、阵发性房颤患者81例,并选择同时期非心源性脑梗死患者115例,比较各组发病72 h之内的血清D-二聚体、纤维蛋白原、脑钠肽(BNP)、C-反应蛋白(CRP),在院住院期间心脏超声测得的左房前后径大小。结果:1) 持续性、阵发性房颤组BNP水平明显高于对照组,差异有显著性(P < 0.05),而持续性和阵发性房颤组之间差异无统计学意义(P > 0.05)。2) 三组发病住院期间测量的左心房前后径大小有明显差异(4.71 ± 0.83, 4.12 ± 0.59, 3.81 ± 0.47),各组间差异有统计学意义(P < 0.05)。3) 多因素logistic回归分析显示,BNP水平升高(OR = 1.02, 95% CI: 1.02~1.03, P < 0.001)和左房前后径增大(cm) (OR = 3.00, 95% CI: 1.04~8.71, P = 0.043)是阵发性房颤类型脑梗死的独立危险因素。结论:房颤引起心源性栓塞患者血浆BNP水平明显高于无心源性脑栓塞患者,房颤患者左心房前后径增大,持续性较阵发性房颤患者更加明显,血清BNP水平升高和左房前后径增大是阵发性房颤心源性脑梗死的独立危险因素。
Abstract: Purpose: By comparing the serum brain natriuretic peptides (BNP), D-dimer, fibrinogen, C-reactive protein (CRP), and the anteroposterior diameter of the left atrium (LA) detected by ultrasound, in patients with cardiogenic stroke caused by different types of atrial fibrillation (AF), to evaluate its value in the diagnosis of cardiogenic stroke to guide treatment and prevent re-embolism. Methods: A retrospective collection of 185 patients with acute cardiogenic cerebral infarction with AF in the Department of Neurology of Qingdao University Affiliated Hospital from June 2017 to June 2020, including 104 patients with persistent atrial fibrillation (PeAF) and 81 patients with paroxysmal atrial fibrillation (PaAF), and 115 patients with ischemic cerebral infarction without AF during the same period were selected. Serum D-dimer, fibrinogen, BNP and CRP in each group within 72 hours of onset, and the anteroposterior diameter of the LA measured by ultrasound during the hospital stay, were compared. Results: 1) The BNP level of PeAF and PaAF group was significantly higher than that of the control group, and the difference is significant (P < 0.05), while the difference between PeAF and PaAF group is not statistically significant (P > 0.05). 2) The anteroposterior diameters of the LA measured among the three groups are significantly different (cm) (4.71 ± 0.83, 4.12 ± 0.59, 3.81 ± 0.47), and the differences between the groups are statistically significant (P < 0.05). 3) Multivariate logistic regression analysis showed that BNP (OR = 1.02, 95%CI: 1.02~1.03, P < 0.001) and LA anteroposterior diameter (OR = 3.00, 95% CI: 1.04~8.71, P = 0.043) are independent risk factors for PaAF with cerebral embolism patients. Conclusion: The serum BNP level of patients with cardiogenic embolism caused by AF is significantly higher than that of patients with non-cardiogenic cerebral embolism. The anteroposterior diameter of LA in patients with AF is enlarged, and the PeAF is more obvious than that in patients with PaAF. Serum BNP and LA anteroposterior diameter are independent risk factors of cardiogenic cerebral embolism caused by PaAF.
文章引用:金玄美, 马爱军, 潘旭东. 血清BNP水平及左房内径对脑梗死合并阵发性房颤的辅助诊断价值[J]. 临床医学进展, 2021, 11(1): 192-198. https://doi.org/10.12677/ACM.2021.111028

参考文献

[1] Kolominsky-Rabas, P.L., Weber, M., Gefeller, O., Neundoerfer, B. and Heuschmann, P.U. (2001) Epidemiology of Ischemic Stroke Subtypes According to TOAST Criteria: Incidence, Recurrence, and Long-Term Survival in Ischemic Stroke Subtypes: A Population-Based Study. Stroke, 32, 2735-2740. [Google Scholar] [CrossRef] [PubMed]
[2] Marini, C., De Santis, F., Sacco, S., Russo, T., Olivieri, L., Totaro, R., et al. (2005) Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke: Results from a Population-Based Study. Stroke, 36, 1115-1119. [Google Scholar] [CrossRef
[3] Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J.J., Blomström-Lundqvist, C., et al. (2020) 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). European Heart Journal, ehaa612. [Google Scholar] [CrossRef] [PubMed]
[4] Rost, N.S., Biffi, A., Cloonan, L., Chorba, J., Kelly, P., Greer, D., et al. (2012) Brain Natriuretic Peptide Predicts Functional Outcome in Ischemic Stroke. Stroke, 43, 441-445. [Google Scholar] [CrossRef
[5] Mukoyama, M., Nakao, K., Hosoda, K., Suga, S., Saito, Y., Ogawa, Y., et al. (1991) Brain Natriuretic Peptide as a Novel Cardiac Hormone in Humans. Evidence for an Exquisite Dual Natriuretic Peptide System, Atrial Natriuretic Peptide and Brain Natriuretic Peptide. Journal of Clinical Investigation, 87, 1402-1412. [Google Scholar] [CrossRef
[6] Maeda, K., Tsutamoto, T., Wada, A., Hisanaga, T. and Hisanaga, T. (1998) Plasma Brain Natriuretic Peptide as a Biochemical Marker of High Left Ventricular End-Diastolic Pressure in Patients with Symptomatic Left Ventricular Dysfunction. American Heart Journal, 135, 825-832. [Google Scholar] [CrossRef
[7] Sakamoto, Y., Suda, S., Matsumoto, N., Aoki, J., Shimoyama, T., Kanamaru, T., et al. (2019) Accurate Etiology Diagnosis in Patients with Stroke and Atrial Fibrillation: A Role for Brain Natriuretic Peptide. Journal of the Neurological Sciences, 400, 153-157. [Google Scholar] [CrossRef] [PubMed]
[8] Tuinenburg, A.E., Brundel, B.J., Van Gelder, I.C., Henning, R.H., Van Den Berg, M.P., Driessen, C., et al. (1999) Gene Expression of the Natriuretic Peptide System in Atrial Tissue of Patients with Paroxysmal and Persistent Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 10, 827-835.
[9] Stanciu, A.E., Vatasescu, R.G., Stanciu, M.M., Serdarevic, N. and Dorobantu, M. (2018) The Role of Pro-Fibrotic Biomarkers in Paroxysmal and Persistent Atrial Fibrillation. Cytokine, 103, 63-68. [Google Scholar] [CrossRef] [PubMed]
[10] Pathan, F., Sivaraj, E., Negishi, K., Rafiudeen, R., Pathan, S., D’Elia, N., et al. (2018) Use of Atrial Strain to Predict Atrial Fibrillation after Cerebral Ischemia. JACC: Cardiovascular Imaging, 11, 1557-1565. [Google Scholar] [CrossRef] [PubMed]
[11] Padfield, G.J., Steinberg, C., Swampillai, J., Qian, H., Connolly, S.J., Dorian, P., et al. (2017) Progression of Paroxysmal to Persistent Atrial Fibrillation: 10-Year Follow-Up in the Canadian Registry of Atrial Fibrillation. Heart Rhythm, 14, 801-807. [Google Scholar] [CrossRef] [PubMed]
[12] Conen, D., Rodondi, N., Müller, A., Beer, J.H., Ammann, P., Moschovitis, G., et al. (2019) Relationships of Overt and Silent Brain Lesions with Cognitive Function in Patients with Atrial Fibrillation. Journal of the American College of Cardiology, 73, 989-999. [Google Scholar] [CrossRef] [PubMed]
[13] Amarenco, P., Bogousslavsky, J., Caplan, L.R., Donnan, G.A. and Hennerici, M.G. (2009) New Approach to Stroke Subtyping: The A-S-C-O (Phenotypic) Classification of Stroke. Cerebrovascular Diseases, 27, 502-508. [Google Scholar] [CrossRef] [PubMed]
[14] Sanna, T., Diener, H.-C., Passman, R.S., Di Lazzaro, V., Bernstein, R.A., Morillo, C.A., et al. (2014) Cryptogenic Stroke and Underlying Atrial Fibrillation. New England Journal of Medicine, 370, 2478-2486.
[15] Inaba, O., Yamauchi, Y., Sekigawa, M., Miwa, N., Yamaguchi, J., Nagata, Y., et al. (2018) Atrial Fibrillation Type Matters: Greater Infarct Volume and Worse Neurological Defects Seen in Acute Cardiogenic Cerebral Embolism Due to Persistent or Permanent Rather than Paroxysmal Atrial Fibrillation. EP Europace, 20, 1591-1597. [Google Scholar] [CrossRef] [PubMed]
[16] Gaita, F., Corsinovi, L., Anselmino, M., Raimondo, C., Pianelli, M., Toso, E., et al. (2013) Prevalence of Silent Cerebral Ischemia in Paroxysmal and Persistent Atrial Fibrillation and Correlation with Cognitive Function. Journal of the American College of Cardiology, 62, 1990-1997. [Google Scholar] [CrossRef] [PubMed]
[17] Hsu, J.C., Chan, P.S., Tang, F.M., Maddox, T.M. and Marcus, G.M. (2015) Differences in Anticoagulant Therapy Prescription in Patients with Paroxysmal versus Persistent Atrial Fibrillation. American Journal of Medicine, 128, 654.e1-654.e10. [Google Scholar] [CrossRef] [PubMed]
[18] Hylek, E.M., Go, A.S., Chang, Y.C., Jensvold, N.G., Henault, L.E., Selby, J.V., et al. (2003) Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. New England Journal of Medicine, 349, 1019-1026. [Google Scholar] [CrossRef
[19] Seet, R.C., Friedman, P.A. and Rabinstein, A.A. (2011) Prolonged Rhythm Monitoring for the Detection of Occult Paroxysmal Atrial Fibrillation in Ischemic Stroke of Unknown Cause. Circulation, 124, 477-486. [Google Scholar] [CrossRef
[20] Healey, J.S., Connolly, S.J., Gold, M.R., Israel, C.W., Van Gelder, I.C., Capucci, A., et al. (2012) Subclinical Atrial Fibrillation and the Risk of Stroke. New England Journal of Medicine, 366, 120-129. [Google Scholar] [CrossRef
[21] Olesen, J.B., Lip, G.Y.H., Hansen, M.L., Tolstrup, J.S., Lindhardsen, J., Selmer, C., et al. (2011) Validation of Risk Stratification Schemes for Predicting Stroke and Thromboembolism in Patients with Atrial Fibrillation: Nationwide Cohort study. BMJ, 342, d124. [Google Scholar] [CrossRef] [PubMed]
[22] Hijazi, Z., Lindbäck, J., Alexander, J.H., Hanna, M., Held, C., Hylek, E.M., et al. (2016) The ABC (Age, Biomarkers, Clinical History) Stroke Risk Score: A Biomarker-Based Risk Score for Predicting Stroke in Atrial Fibrillation. European Heart Journal, 37, 1582-1590. [Google Scholar] [CrossRef] [PubMed]